caa a22 4500 465737110 CHVBK 20180323111757.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF02244093 doi (NATIONALLICENCE)springer-10.1007/BF02244093 Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease [Elektronische Daten] [S. Close, P. Elliott, A. Hayes, A. Marriott] A modified primate model of Parkinson's disease was developed to assess the effectiveness of various agents that act via dopamine, acetylcholine, serotonin or glutamate systems. Using a MPTP dosing regimen a reversible parkinsonian-like syndrome was produced in the marmoset. An obvious advantage of such a protocol is that it allows multiple drug studies to be undertaken in animals, without the need for prolonged anti-parkinsonian therapy to maintain their health. Results show that dopamine D2 agonists (bromocriptine, quinpirole, N,N-dipropyl,A,5,6-DTN, (+)3PPP and PHNO), anti-muscarinics (atropine, scopolamine and benztropine), in addition tol-DOPA and nomifensine, all reduced the bradykinesia induced by MPTP. The D1 agonist SKF-38393 and the partial dopamine agonist (−)3PPP were both ineffective. Finally, agents with potential therapeutic use in Parkinson's disease were also tested. However, a glutamate antagonist (MK801) and three serotonin antagonists (ritanserin, ketanserin and ICI 170,809) were all unable to alter the MPTP effects, at the doses used in our study. Springer-Verlag, 1990 Dopamine agonists nationallicence 5HT antagonists nationallicence Muscarinic antagonists nationallicence Glutamate antagonists nationallicence Marmoset nationallicence Close S. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut Elliott P. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut Hayes A. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut Marriott A. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut Psychopharmacology Springer-Verlag 102/3(1990-11-01), 295-300 0033-3158 102:3<295 1990 102 213 https://doi.org/10.1007/BF02244093 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244093 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Close S. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut NATIONALLICENCE 700 1- Elliott P. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut NATIONALLICENCE 700 1- Hayes A. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut NATIONALLICENCE 700 1- Marriott A. Department of Neuropharmacology, Glaxo Group Research Ltd., SG12 ODP, Ware, Hertfordshire, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 102/3(1990-11-01), 295-300 0033-3158 102:3<295 1990 102 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer